Narayana Hrudayalaya Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Narayana Hrudayalaya (NH) Q4 results for FY26 are expected in May 2026. With Q3 FY26 revenue of Rs 1285 Cr and PAT of Rs 158 Cr as the base, the street is watching closely for margin trajectory and management guidance on FY27 demand.

Get Free SEBI-Registered Research on Narayana Hrudayalaya — Click Here

Narayana Hrudayalaya Q4 FY26 Earnings Preview — What to Expect

India's healthcare diagnostics sector maintains solid growth momentum in Q4 FY26, backed by rising health awareness, insurance penetration expansion and a robust preventive testing trend driving test volumes across the country.

Narayana Hrudayalaya Q4 Results 2026 — Date and Key Estimates

Parameter	Q3 FY26 Actual	Q4 FY26 Estimate	YoY Growth
Revenue (Rs Cr)	1285	1388	+8%
PAT (Rs Cr)	158	178	+13%
EBITDA Margin	–	12.8%	Improvement expected
Results Date	–	May 2026	–
Dividend History	Rs 3.00 per share
Dividend Expectation	Rs 4.00 final dividend expected

Estimates based on analyst consensus as of April 2026. Actual results may vary.

Track Narayana Hrudayalaya live price, FII/DII activity and fundamentals on Univest Screener

5 Reasons Narayana Hrudayalaya Q4 Results Could Beat Estimates

Preventive Healthcare Demand

Growing health consciousness and rising insurance coverage are driving strong demand for health checkup packages and chronic disease monitoring tests, both of which carry higher margins.

Network Expansion into Tier-2 and Tier-3 Cities

Diagnostic chains are capturing untapped demand in semi-urban India through hub-and-spoke lab models and home collection services, expanding addressable market significantly.

Specialised Testing Growth

High-value testing in genomics, immunology, molecular diagnostics and oncology is growing rapidly, improving revenue per patient and blended margin profiles.

Institutional and B2B Business

Tie-ups with hospitals, corporates and insurance companies for dedicated diagnostic services create stable, recurring B2B revenue with lower customer acquisition costs.

Digital Health Platform Integration

Digital booking, home collection and online reporting platforms are improving patient experience, loyalty and repeat testing rates, reducing churn and acquisition costs.

5 Key Risks to Watch in Narayana Hrudayalaya Q4 Results

Price War from Competition

Aggressive discounting by unorganised labs and newer entrant chains pressures realisations and tests-per-patient metrics across markets.

Regulatory Quality Requirements

NABL accreditation maintenance, CGHS panel compliance and quality audits add ongoing operational costs that weigh on margins.

Capital Intensity of Network Expansion

Setting up new collection centres and processing labs requires significant capital; ROI typically takes 2-3 years to fully materialise.

Equipment Upgrade Capex

Rapid diagnostic technology evolution requires continuous equipment replacement investment, adding recurring capex pressure.

Insurance Reimbursement Pressure

Health insurers negotiating lower reimbursement rates for diagnostic tests can reduce revenue per test over time.

Analyst Ratings and Target Price for Narayana Hrudayalaya

Brokerage	Rating	Key Thesis
Emkay Global	Buy	Network expansion and volume recovery on track
JM Financial	Neutral	Competition intensity remains a concern
ICICI Direct	Buy	Preventive health demand and B2B growth drivers

Analyst ratings are for informational purposes only. Not investment advice.

Subscribe to Univest Pro for SEBI-registered entry, target and stop-loss levels on Narayana Hrudayalaya

Frequently Asked Questions — Narayana Hrudayalaya Q4 Results 2026

Q: When will Narayana Hrudayalaya announce Q4 FY26 results?

Narayana Hrudayalaya is expected to announce Q4 FY26 results in May 2026. Track the exact date on Univest Screener.

Q: What revenue is expected for Narayana Hrudayalaya Q4 FY26?

Analyst consensus estimates Narayana Hrudayalaya Q4 FY26 revenue at approximately Rs 1388 Cr, representing approximately 8% year-on-year growth.

Q: What PAT is expected for Narayana Hrudayalaya in Q4 FY26?

Estimated PAT for Narayana Hrudayalaya Q4 FY26 is approximately Rs 178 Cr, up approximately 13% year-on-year.

Q: Will Narayana Hrudayalaya declare a dividend in Q4 FY26?

Historical dividend pattern: Rs 3.00 per share. Q4 FY26 expectation: Rs 4.00 final dividend expected.

Q: What is the current share price of Narayana Hrudayalaya?

Narayana Hrudayalaya (NH) is currently trading at approximately Rs 1408 with a market capitalisation of Rs 28,000 Cr. Track live on Univest Screener.

Q: Is Narayana Hrudayalaya a buy before Q4 results?

This article does not constitute investment advice. Consult a SEBI-registered financial advisor before making any investment decision.

Disclaimer: Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. SEBI Registration: INH000012449.

Recent Article

Kridhan Infra Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Krebs Biochemicals and Industries Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

KRBL Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

KPIT Technologies Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Kothari Sugars and Chemicals Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook